Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 6:47 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2377–2400 of 3,287 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Progenitor Cells Clear all

Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Undifferentiated Leukemia, Biphenotypic Leukemia, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma
Interventions: MRI and cognitive evaluation, brain MRI study and a brief neuropsychological evaluation; Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2015
U.S. locations: 2
States / cities: New York, New York

Conditions: Multiple Myeloma
Interventions: Placebo, Ixazomib; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 706 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 23
States / cities: Fountain Valley, California • Los Angeles, California • Oceanside, California + 19 more

Conditions: Inherited Immune Deficiencies
Interventions: Campath 1H, Busulfan, Horse Anti-human Thymocyte Globulin (h-ATG), Total Body Irradiation (TBI), Sirolimus or equivalent based on response; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Years to 40 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Graft Vs Host Disease, Vitamin A Deficiency, Vitamin D Deficiency
Interventions: Vitamin A, Placebo; Drug · Other
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 3
States / cities: Tampa, Florida • Buffalo, New York • Columbus, Ohio

Conditions: Caregiver, Hematologic Malignancy
Interventions: Positive Psychology Intervention; Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hematopoietic Steam Cell Transplantation (HCT)
Interventions: Acceptance and Commitment Therapy (ACT); Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Raleigh, North Carolina

Conditions: Diabetes Mellitus, Ischemic Heart Disease
Interventions: 100 million Allogeneic Mesenchymal Human Stem Cells, Placebo; Drug · Other
Lead sponsor: Joshua M Hare; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Neoplasms
Interventions: Ready to CARE program; Behavioral
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Crohn Disease
Interventions: Stem Cell Transplant; Procedure
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Systemic Lupus Erythematosus
Interventions: anti-thymocyte globulin, cyclophosphamide, filgrastim, CD34+ Peripheral Blood Stem Cell Reinfusion; Drug · Procedure
Lead sponsor: Northwestern Memorial Hospital; Other
Eligibility: 0 Years to 59 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 2
States / cities: Chicago, Illinois • Madison, Wisconsin

Conditions: Sickle Cell Disease
Interventions: Not listed
Lead sponsor: Emory University; Other
Eligibility: 6 Months to 21 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Immunodeficiency, Hematopoietic Stem Cell Transplantation
Interventions: Allogeneic HSCT, Busulfan test dose, Mycophenolate mofetil (MMF), Tacrolimus, Busulfan, Total Body Irradiation (TBI), Fludarabine, Cyclophosphamide (CY), Post-Transplant Cyclophosphamide (PTCY); Procedure · Drug · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hematopoietic Stem Cell Transplant, CAR-T Cell Therapy
Interventions: Step Up, Usual Care Plus (UC+); Behavioral · Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Neurofibromatosis Type 1, Tumors of the Central Nervous System
Interventions: Collection of Stem Cells; Diagnostic Test
Lead sponsor: Roger Packer; Other
Eligibility: Not listed
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2025
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Crohn Disease, Inflammatory Bowel Diseases
Interventions: ExoFlo; Biological
Lead sponsor: Direct Biologics, LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Los Angeles, California • New York, New York

Conditions: Leukemia, Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Severe Aplastic Anemia, Allogeneic Transplant
Interventions: Cyclophosphamide; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years to 65 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: CD34 Selected Peripheral Blood Stem Cell Graft
Interventions: PET/CT scans, MRI; Device
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 4
States / cities: Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 1 more

Conditions: Chediak-Higashi Syndrome, Graft Versus Host Disease, X-Linked Lymphoproliferative Syndrome, Familial Erythrophagocytic Lymphohistiocytosis, Hemophagocytic Lymphohistiocytosis, Virus-Associated Hemophagocytic Syndrome
Interventions: anti-thymocyte globulin, busulfan, cyclophosphamide, cyclosporine, etoposide, filgrastim, methotrexate, allogeneic hematopoietic stem cell transplantation; Drug · Procedure
Lead sponsor: Fairview University Medical Center; Other
Eligibility: 0 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Chronic Lymphocytic Leukemia
Interventions: GM-K562 vaccine, stem cell transplantation; Biological · Procedure
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Leukemia, Lymphoma, Graft Versus Host Disease
Interventions: cyclosporine, cyclosporine and methotrexate; Drug
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2003
U.S. locations: 12
States / cities: Los Angeles, California • Jacksonville, Florida • Atlanta, Georgia + 9 more

Conditions: Transplantation Infection
Interventions: Cidofovir, No Cidofovir; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 6 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Childhood Acute Myeloid Leukemia in Remission, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia
Interventions: busulfan, etoposide, aldesleukin, peripheral blood stem cell transplantation; Drug · Biological · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Up to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2015
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Miscellaneous Peripheral Blood Cell Abnormalities
Interventions: TXA127, Neupogen (filgrastim); Drug
Lead sponsor: Tarix Pharmaceuticals; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions: Decitabine plus Fludarabine and Busulfan; Drug
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 45 Years to 80 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Hackensack, New Jersey

Search by objective public record fields.

Structural Imaging and Cognitive Functions in Adult Stem Cell Transplant Recipients Treated With Chemotherapy Alone or in Combination With Radiotherapy

A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)

Donor Stem Cell Transplantation for Congenital Immunodeficiencies

Vitamin A Supplementation in Allogeneic Stem Cell Transplantation.

Proof-of-Concept Trial of a Positive Psychology Intervention for Caregivers of Patients Undergoing HSCT

ACT to Reduce Morbidity and Mortality in Hematopoietic Stem Cell Transplant (HCT) Patients

Allogeneic Mesenchymal Human Stem Cell Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects With Symptomatic Ischemic Heart Disease. (ACESO-IHD)

CAREgiver Study for Patients Undergoing HSCT

Immune Ablation and Stem Cell Support for Crohn's Disease

Phase I Study of Immune Ablation and CD34+ Peripheral Blood Stem Cell Support in Patients With Systemic Lupus Erythematosus

Analysis of T-Cell Immune Reconstitution Following Allogeneic Hematopoietic BMT for Severe SCD

A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome

Coping Skills Training for Symptom Management and Daily Steps (Step Up)

Stem Cells in NF1 Patients With Tumors of the Central Nervous System

Study of ExoFlo for the Treatment of Medically Refractory Crohn's Disease

Post Transplant Cyclophosphamide (Cytoxan) for GvHD Prophylaxis

A Study to Assess Thymic Function Using PET/CT and MRI

Pilot Study of Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Life Threatening Hemophagocytic Disorders

Reduced Intensity Stem Cell Transplantation for Chronic Lymphocytic Leukemia Followed by Vaccination

Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation

Cidofovir Versus Best Supportive Care for Hemorrhagic Cystitis

Busulfan and Etoposide Followed by Peripheral Blood Stem Cell Transplant and Low-Dose Aldesleukin in Treating Patients With Acute Myeloid Leukemia

Safety and Efficacy of TXA127 and Neupogen to Increase Peripheral Blood Stem Cells (PBSCs)

PRO#0118: Decitabine Plus Mini Flu-Bu